GlassScriptPhysician profile
Shanon Lynn Custer
NPI 1902870637
$4,783.34
in general payments reported to CMS, 2019-2025
37 companies · $360 in 2025
The $360 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,953 · 2020: $562 · 2021: $435 · 2022: $490 · 2023: $416 · 2024: $568 · 2025: $360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,343.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,342.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $730.34 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Sunovion Pharmaceuticals INC. | $526.18 | 2019-2022 | |
| Pfizer INC. | $384.55 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $334.30 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Amgen INC. | $329.06 | 2019-2025 | Evenity, Prolia, Tavneos |
| Astrazeneca Pharmaceuticals LP | $306.44 | 2019-2023 | Breztri |
| Sanofi-Aventis U.S. LLC | $306.33 | 2019-2022 | |
| Astellas Pharma US INC | $227.65 | 2019-2022 | |
| Lilly USA, LLC | $195.63 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Mylan Specialty L.P. | $181.48 | 2019-2024 | Yupelri |
| Dexcom, INC. | $166.90 | 2022-2024 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Merck Sharp & Dohme LLC | $124.19 | 2019-2023 | Belsomra, Steglatro |
| Glaxosmithkline, LLC. | $92.57 | 2021-2025 | Arexvy, Trelegy Ellipta, Bexsero |
| Novartis Pharmaceuticals Corporation | $88.23 | 2023-2025 | |
| Abbvie INC. | $80.27 | 2023-2024 | Vraylar |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shanon Custer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.